癲癇對患者認知影響的研究現狀及進展_Journal of Epilepsy

Authors：

尹江寧 ,  張鴻

中國醫科大學附屬盛京醫院神經內科（沈陽 ?110004）;

Corresponding?author：

張鴻, Email: zhangh.7211@163.com

Keywords：

癲癇; 認知障礙; 現狀; 進展

DOI：

10.7507/2096-0247.20190036

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

癲癇病因較復雜，與患者發病年齡、情緒、心理因素以及癲癇類型等密切相關。認知障礙會導致患者幼年時期學習能力下降，成年后嚴重影響其日常生活及工作，對患者及家屬的身心造成了嚴重傷害，同時帶來較重負擔，極大影響了患者的心理狀態。近年來，隨著癲癇患者認知障礙的發病率逐漸升高，二者共病逐漸引起了廣泛關注，癲癇共患認知障礙發病機制尚不明確，但其造成的嚴重影響值得臨床重視。文章從癲癇引發認知損害的可能機制、癲癇發病形式、社會因素以及生理因素、癲癇對患者認知功能的影響等方面進行簡要綜述，旨在探索其發生認知功能損害的原因，為提高患者的生活質量提供參考依據。

Citation： 尹江寧, 張鴻. 癲癇對患者認知影響的研究現狀及進展. Journal of Epilepsy, 2019, 5(3): 200-204. doi: 10.7507/2096-0247.20190036 Copy

1.	Lattanzi S, Brigo F, Trinka E, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs, 2018, 78(17): 1791-1804.
2.	Paudel YN, Shaikh MF, Chakraborti A, et al. HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, andcognitivedysfunction. Front Neurosci, 2018, 12: 628.
3.	Su DJ, Lu JF, Lin LJ, et al. SCN2A mutation in an infant presenting with migrating focal seizures and infantile spasm responsive to a ketogenic diet. Brain Dev, 2018, 40(8): 724-727.
4.	Salvato G, Scarpa P, Francione S, et al. Declarative long-term memory and the mesial temporal lobe: insights from a 5-year postsurgery follow-up study on refractory temporal lobe epilepsy. Epilepsy Behav, 2016, 64(Pt A): 102-109.
5.	Feldman L, Lapin B, Busch RM, et al. Evaluating subjective cognitive impairment in the adult epilepsy clinic: effects of depression, number of antiepileptic medications, and seizure frequency. Epilepsy Behav, 2018, 81: 18-24.
6.	Lee EH. Epilepsy syndromes during the first year of life and the usefulness of an epilepsy gene panel. Korean J Pediatr, 2018, 61(4): 101-107.
7.	陳珉, 傅建梅. 癲癇患者的認知功能評估. 中華全科醫學, 2013, 11(3): 1674-4152.
8.	Ribierre T, Deleuze C, Bacq A, et al. Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy. J Clin Invest, 2018, 128(6): 2452-2458.
9.	Warburton A, Miyajima F, Shazadi K, et al. NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy. Epilepsy Behav, 2016, 54: 117-127.
10.	Baxendale S, McGrath K, Donnachie E, et al. The role of obesity in cognitive dysfunction in people with epilepsy. Epilepsy Behav, 2015, 45: 187-190.
11.	Tuchscherer V, Seidenberg M, Pulsipher D, et al. Extrahippocampal integrity in temporal lobe epilepsy and cognition: thalamus and executive functioning. EpilepsyBehav, 2010, 17(4): 478-482.
12.	Shetty AK. Hippocampal injury-induced cognitive and mood dysfunction, altered neurogenesis, and epilepsy: can early neural stem cell grafting intervention provide protection? Epilepsy Behav, 2014, 38: 117-124.
13.	Raimalwalla T, Udani V, Mhatre D. A Retrospective analysis of the long-term outcome of drug-resistant epilepsy in children treated inurban India. Child Neurol Open, 2018, 5: 2329048X18795277.
14.	Theodore WH, Wiggs EA, Martinez AR, et al. Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy. Epilepsia, 2012, 53(1): 129-133.
15.	竇智, 陳穎, 蔡雁飛, 等. 藥物難治性額葉、顳葉癲癇患者認知功能障礙特點及影響分析. 癲癇與神經電生理學雜志, 2018, 27(3): 142-145.
16.	de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis, 2018, 13(1): 157.
17.	Han M, Kim S. Effects of antiepileptic drugs on language abilities in benign epilepsy of childhood with centrotemporal spikes. J Rare Dis, 2018, 13(1): 157.
18.	Michel M, Green CL, Lyons LC. PKA and PKC are required for long-term but not short-term in vivo operant memory inplysia. Learn Mem, 2010, 18(1): 19-23.
19.	El-Enin HA, Al-Shanbari AH. Nanostructured liquid crystalline formulation as a remarkable new drug delivery system of anti-epileptic drugs for treating children patients. Saudi Pharm J, 2018, 26(6): 790-800.
20.	Dutra MRH, Feliciano RDS, Jacinto KR, et al. Protective role of UCP2 in oxidative stress and apoptosis during the silent phase of an experimental model of epilepsy induced by pilocarpine. Oxid Med Cell Longev, 2018, 20: 6736721.
21.	Kingswood JC, d'Augères GB, Belousova E, et al. Tuberous sclerosis registry to increase disease awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis, 2017, 12(1): 2.
22.	deSena AD, Do T, Schulert GS. Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade. J Neuroinflammation, 2018, 15(1): 38.
23.	van Scheppingen J, Mills JD, Zimmer TS, et al. MiR147b: a novel key regulator of interleukin 1 beta-mediated inflammation in human astrocytes. Glia, 2018, 66(5): 1082-1097.
24.	Zhou H, Wang N, Xu L, et al. The efficacy of gastrodin in combination with folate and vitamin B12 on patients with epilepsy after stroke and its effect on HMGB-1, IL-2 and IL-6 serum levels. Exp Ther Med, 2017, 14(5): 4801-4806.
25.	于曉赟, 劉松巖, 王立波, 等. 臨床下癇樣放電對成人癲癇患者認知功能的影響. 中華神經科雜志, 2018, 51(5): 349-354.
26.	Wijnen BFM, van Mastrigt GAPG, Evers SMAA, et al. Asystematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia, 2017, 58(5): 706-726.
27.	Tigistu M, Azale T, Kebebe H, et al. Frequency of seizure attack and associated factors among patients with epilepsy at university of gondar referral hospital: a cross-sectional study, gondar, north west ethiopia, 2017. BMC Res Notes, 2018, 11(1): 652.
28.	Shatskikh TN, Raghavendra M, Zhao Q, et al. Electrical induction of spikes in the hippocampus impairs recognition capacity and spatial memory in rats. Epilepsy Behav, 2006, 9(4): 549-556.
29.	Schougaard LMV, de Thurah A, Bech P, et al. Test-retest reliability and measurement error of the danish WHO-5 well-being index in outpatients with epilepsy. HealthQual Life Outcomes, 2018, 16(1): 175.
30.	周艷輝, 周峰, 余丹, 等. 托吡酯治療腦梗死后繼發癲癇臨床效果及認知功能分析. 解放軍醫藥雜志, 2018, 30(2): 94-97.
31.	Cumbo E, Ligori LD. Levetiracetam, lamotrigine andphenobarbital in patients with epileptic seizures and alzheimer's disease. Epilepsy Behav, 2010, 17(4): 461-466.
32.	Tonekaboni SH, Beyraghi N, Tahbaz HS, et al. Neurocognitiveeffects of phenobarbital discontinuation in epileptic children. Epilepsy Behav, 2006, 8(1): 145-148.
33.	王珊丹, 楊昕. 左乙拉西坦、拉莫三嗪與奧卡西平在癲癇患兒中兩年保留率及耐受性比較. 中國生化藥物雜志, 2017, 37(8): 185-188.
34.	Xie W, Ross EE, Kramer MA, et al. Timing matters: impact of anticonvulsant drug treatment and spikes on seizure risk in benign epilepsy with centrotemporal spikes. Epilepsia Open, 2018, 22, 3(3): 409-417.
35.	Sever RW, Vivas AC, Vale FL, et al. Wada asymmetry in patients with drug-resistant mesial temporal lobe epilepsy: implications for postoperative neuropsychological outcomes. Epilepsia Open, 2018, 3(3): 399-408.
36.	Reilly C, Atkinson P, Memon, et al. Child and parental sleep in young children with epilepsy: a population-based case-control study. Epilepsia Open, 2018, 3(3): 383-391.
37.	Sakuma H, Tanuma N, Kuki I, et al. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatry, 2015, 86(7): 820-822.
38.	Liu J, Tong L, Song S, et al. Novel and de novo mutations in pediatric refractory epilepsy. Mol Brain, 2018, 11(1): 48.
39.	Balottin L, Mannarini S, Candeloro D, et al. Rorschach evaluation of personality and emotional characteristics in adolescents with migraine versus epilepsy and controls. Front Neurol, 2018, 9: 160.
40.	Boling W, Means M, Fletcher A, et al. Quality of life and stigma in epilepsy, perspectives from selected regions of asia and sub-saharan africa. Brain Sci, 2018, 8(4): pii: E59.
41.	Nakahara S, Adachi M, Ito H, et al. Hippocampal pathophysiology: commonality shared by temporal lobe epilepsy and psychiatric disorders. Neurosci J, 2018, 2018: 4852359.
42.	Choudhary S, Niranjan N, Khichar S, et al. Behavioral problems and intelligence quotient changes in pediatric epilepsy: a case-control study. J Neurosci Rural Pract, 2017, 8(4): 617-621.
43.	Leeman-Markowski BA, Schachter SC. Treatment of cognitive deficitsinepilepsy. Neurol Clin, 2016, 34(1): 183-204.
44.	Calhoun JD, Vanoye CG, Kok F, et al. Characterization of a KCNB1 variant associated with autism, intellectual disability, and epilepsy. Neurol Genet, 2017, 3(6): e198.
45.	IJff DM, Postulart D, Lambrechts DAJE, et al. Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: a randomized controlled trial. Epilepsy Behav, 2016, 60: 153-157.
46.	Allendorfer JB, Arida RM. Role of physical activity and exercise in alleviating cognitive impairment in people with epilepsy. Clin Ther, 2018, 40(1): 26-34.

1. Lattanzi S, Brigo F, Trinka E, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs, 2018, 78(17): 1791-1804.
2. Paudel YN, Shaikh MF, Chakraborti A, et al. HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, andcognitivedysfunction. Front Neurosci, 2018, 12: 628.
3. Su DJ, Lu JF, Lin LJ, et al. SCN2A mutation in an infant presenting with migrating focal seizures and infantile spasm responsive to a ketogenic diet. Brain Dev, 2018, 40(8): 724-727.
4. Salvato G, Scarpa P, Francione S, et al. Declarative long-term memory and the mesial temporal lobe: insights from a 5-year postsurgery follow-up study on refractory temporal lobe epilepsy. Epilepsy Behav, 2016, 64(Pt A): 102-109.
5. Feldman L, Lapin B, Busch RM, et al. Evaluating subjective cognitive impairment in the adult epilepsy clinic: effects of depression, number of antiepileptic medications, and seizure frequency. Epilepsy Behav, 2018, 81: 18-24.
6. Lee EH. Epilepsy syndromes during the first year of life and the usefulness of an epilepsy gene panel. Korean J Pediatr, 2018, 61(4): 101-107.
7. 陳珉, 傅建梅. 癲癇患者的認知功能評估. 中華全科醫學, 2013, 11(3): 1674-4152.
8. Ribierre T, Deleuze C, Bacq A, et al. Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy. J Clin Invest, 2018, 128(6): 2452-2458.
9. Warburton A, Miyajima F, Shazadi K, et al. NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy. Epilepsy Behav, 2016, 54: 117-127.
10. Baxendale S, McGrath K, Donnachie E, et al. The role of obesity in cognitive dysfunction in people with epilepsy. Epilepsy Behav, 2015, 45: 187-190.
11. Tuchscherer V, Seidenberg M, Pulsipher D, et al. Extrahippocampal integrity in temporal lobe epilepsy and cognition: thalamus and executive functioning. EpilepsyBehav, 2010, 17(4): 478-482.
12. Shetty AK. Hippocampal injury-induced cognitive and mood dysfunction, altered neurogenesis, and epilepsy: can early neural stem cell grafting intervention provide protection? Epilepsy Behav, 2014, 38: 117-124.
13. Raimalwalla T, Udani V, Mhatre D. A Retrospective analysis of the long-term outcome of drug-resistant epilepsy in children treated inurban India. Child Neurol Open, 2018, 5: 2329048X18795277.
14. Theodore WH, Wiggs EA, Martinez AR, et al. Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy. Epilepsia, 2012, 53(1): 129-133.
15. 竇智, 陳穎, 蔡雁飛, 等. 藥物難治性額葉、顳葉癲癇患者認知功能障礙特點及影響分析. 癲癇與神經電生理學雜志, 2018, 27(3): 142-145.
16. de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis, 2018, 13(1): 157.
17. Han M, Kim S. Effects of antiepileptic drugs on language abilities in benign epilepsy of childhood with centrotemporal spikes. J Rare Dis, 2018, 13(1): 157.
18. Michel M, Green CL, Lyons LC. PKA and PKC are required for long-term but not short-term in vivo operant memory inplysia. Learn Mem, 2010, 18(1): 19-23.
19. El-Enin HA, Al-Shanbari AH. Nanostructured liquid crystalline formulation as a remarkable new drug delivery system of anti-epileptic drugs for treating children patients. Saudi Pharm J, 2018, 26(6): 790-800.
20. Dutra MRH, Feliciano RDS, Jacinto KR, et al. Protective role of UCP2 in oxidative stress and apoptosis during the silent phase of an experimental model of epilepsy induced by pilocarpine. Oxid Med Cell Longev, 2018, 20: 6736721.
21. Kingswood JC, d'Augères GB, Belousova E, et al. Tuberous sclerosis registry to increase disease awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis, 2017, 12(1): 2.
22. deSena AD, Do T, Schulert GS. Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade. J Neuroinflammation, 2018, 15(1): 38.
23. van Scheppingen J, Mills JD, Zimmer TS, et al. MiR147b: a novel key regulator of interleukin 1 beta-mediated inflammation in human astrocytes. Glia, 2018, 66(5): 1082-1097.
24. Zhou H, Wang N, Xu L, et al. The efficacy of gastrodin in combination with folate and vitamin B12 on patients with epilepsy after stroke and its effect on HMGB-1, IL-2 and IL-6 serum levels. Exp Ther Med, 2017, 14(5): 4801-4806.
25. 于曉赟, 劉松巖, 王立波, 等. 臨床下癇樣放電對成人癲癇患者認知功能的影響. 中華神經科雜志, 2018, 51(5): 349-354.
26. Wijnen BFM, van Mastrigt GAPG, Evers SMAA, et al. Asystematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia, 2017, 58(5): 706-726.
27. Tigistu M, Azale T, Kebebe H, et al. Frequency of seizure attack and associated factors among patients with epilepsy at university of gondar referral hospital: a cross-sectional study, gondar, north west ethiopia, 2017. BMC Res Notes, 2018, 11(1): 652.
28. Shatskikh TN, Raghavendra M, Zhao Q, et al. Electrical induction of spikes in the hippocampus impairs recognition capacity and spatial memory in rats. Epilepsy Behav, 2006, 9(4): 549-556.
29. Schougaard LMV, de Thurah A, Bech P, et al. Test-retest reliability and measurement error of the danish WHO-5 well-being index in outpatients with epilepsy. HealthQual Life Outcomes, 2018, 16(1): 175.
30. 周艷輝, 周峰, 余丹, 等. 托吡酯治療腦梗死后繼發癲癇臨床效果及認知功能分析. 解放軍醫藥雜志, 2018, 30(2): 94-97.
31. Cumbo E, Ligori LD. Levetiracetam, lamotrigine andphenobarbital in patients with epileptic seizures and alzheimer's disease. Epilepsy Behav, 2010, 17(4): 461-466.
32. Tonekaboni SH, Beyraghi N, Tahbaz HS, et al. Neurocognitiveeffects of phenobarbital discontinuation in epileptic children. Epilepsy Behav, 2006, 8(1): 145-148.
33. 王珊丹, 楊昕. 左乙拉西坦、拉莫三嗪與奧卡西平在癲癇患兒中兩年保留率及耐受性比較. 中國生化藥物雜志, 2017, 37(8): 185-188.
34. Xie W, Ross EE, Kramer MA, et al. Timing matters: impact of anticonvulsant drug treatment and spikes on seizure risk in benign epilepsy with centrotemporal spikes. Epilepsia Open, 2018, 22, 3(3): 409-417.
35. Sever RW, Vivas AC, Vale FL, et al. Wada asymmetry in patients with drug-resistant mesial temporal lobe epilepsy: implications for postoperative neuropsychological outcomes. Epilepsia Open, 2018, 3(3): 399-408.
36. Reilly C, Atkinson P, Memon, et al. Child and parental sleep in young children with epilepsy: a population-based case-control study. Epilepsia Open, 2018, 3(3): 383-391.
37. Sakuma H, Tanuma N, Kuki I, et al. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatry, 2015, 86(7): 820-822.
38. Liu J, Tong L, Song S, et al. Novel and de novo mutations in pediatric refractory epilepsy. Mol Brain, 2018, 11(1): 48.
39. Balottin L, Mannarini S, Candeloro D, et al. Rorschach evaluation of personality and emotional characteristics in adolescents with migraine versus epilepsy and controls. Front Neurol, 2018, 9: 160.
40. Boling W, Means M, Fletcher A, et al. Quality of life and stigma in epilepsy, perspectives from selected regions of asia and sub-saharan africa. Brain Sci, 2018, 8(4): pii: E59.
41. Nakahara S, Adachi M, Ito H, et al. Hippocampal pathophysiology: commonality shared by temporal lobe epilepsy and psychiatric disorders. Neurosci J, 2018, 2018: 4852359.
42. Choudhary S, Niranjan N, Khichar S, et al. Behavioral problems and intelligence quotient changes in pediatric epilepsy: a case-control study. J Neurosci Rural Pract, 2017, 8(4): 617-621.
43. Leeman-Markowski BA, Schachter SC. Treatment of cognitive deficitsinepilepsy. Neurol Clin, 2016, 34(1): 183-204.
44. Calhoun JD, Vanoye CG, Kok F, et al. Characterization of a KCNB1 variant associated with autism, intellectual disability, and epilepsy. Neurol Genet, 2017, 3(6): e198.
45. IJff DM, Postulart D, Lambrechts DAJE, et al. Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: a randomized controlled trial. Epilepsy Behav, 2016, 60: 153-157.
46. Allendorfer JB, Arida RM. Role of physical activity and exercise in alleviating cognitive impairment in people with epilepsy. Clin Ther, 2018, 40(1): 26-34.

Previous Article
自身免疫性腦炎繼發癲癇風險的研究進展
Next Article
丙戊酸鈉所致震顫的臨床特征及診治進展

Journal of Epilepsy

癲癇對患者認知影響的研究現狀及進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content